Table 1. Limiting dilution analysis using human ATC cell lines in a subcutaneous mouse model of thyroid carcinoma.
| Cell line | In vivo passage | Number cells injected | Incidence | Latency (days) |
| THJ-11T | primary | 500,000 | 5/5 | 28 |
| THJ-11T | secondary | 500,000 | 5/5 | 27–28 |
| THJ-11T | secondary | 10,000 | 5/5 | 35 |
| THJ-11T | secondary | 1,000 | 5/5 | 28–35 |
| THJ-11T | tertiary | 500,000 | 5/5 | 7–14 |
| THJ-11T | tertiary | 10,000 | 5/5 | 21–28 |
| THJ-11T | tertiary | 1,000 | 4/5 | 35–42 |
| THJ-16T | primary | 500,000 | 4/5 | 28–70 |
| THJ-16T | secondary | 500,000 | 5/5 | 14 |
| THJ-16T | secondary | 10,000 | 5/5 | 28–49 |
| THJ-16T | secondary | 1,000 | 4/5 | 38–49 |
| THJ-16T | tertiary | 500,000 | 5/5 | 7 |
| THJ-16T | tertiary | 10,000 | 5/5 | 21–28 |
| THJ-16T | tertiary | 1,000 | 5/5 | 35–42 |
| THJ-21T | primary | 500,000 | 4/4 | 56–77 |
| THJ-21T | secondary | 500,000 | 5/5 | 14 |
| THJ-21T | tertiary | 500,000 | 5/5 | 7–14 |
| THJ-21T | tertiary | 10,000 | 5/5 | 35–36 |
| THJ-21T | tertiary | 1,000 | 3/4 | 49 |
| THJ-29T | primary | 500,000 | 3/3 | 56–91 |
| THJ-29T | secondary | 500,000 | 5/5 | 14–21 |
| THJ-29T | secondary | 10,000 | 4/5 | 28 |
| THJ-29T | secondary | 1,000 | 5/5 | 36–77 |
| THJ-29T | tertiary | 500,000 | 3/3 | 7 |
| THJ-29T | tertiary | 10,000 | 3/3 | 21 |
| THJ-29T | tertiary | 1,000 | 4/4 | 21 |
| THJ-11T | thyrosphere | 10,000 | 5/5 | 42–77 |
| THJ-11T | thyrosphere | 5,000 | 5/5 | 63–77 |
| THJ-11T | thyrosphere | 1,000 | 5/5 | 70–105 |